Japanese drug-making giant, Takeda Pharmaceutical Co. , is eyeing Saudi Arabia as a key Middle East market as it aims to boost global sales by more than 50 percent to 5 trillion yen ($48.01 billion) over the next decade. The Tokyo-headquartered company has placed its focus on providing products to the Kingdom in areas such as oncology, rare diseases, gastroenterology, and plasma-derived therapies. Rodrigo Rodriguez, Takeda’s general manager for the ...